• LAST PRICE
    48.4800
  • TODAY'S CHANGE (%)
    Trending Up1.5300 (3.2588%)
  • Bid / Lots
    43.6300/ 1
  • Ask / Lots
    48.3600/ 2
  • Open / Previous Close
    47.6000 / 46.9500
  • Day Range
    Low 47.5600
    High 49.2800
  • 52 Week Range
    Low 3.6900
    High 53.8200
  • Volume
    205,377
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 46.95
TimeVolumeSLNO
09:32 ET126947.6
09:43 ET287748.24
09:45 ET97247.96
09:48 ET10048.58
09:50 ET20048.77
09:52 ET169649.01
09:54 ET70049.26
09:56 ET30049.2
09:59 ET74848.65
10:01 ET50048.72
10:08 ET40048.36
10:10 ET110048.19
10:12 ET148548.525
10:14 ET10048.675
10:15 ET10048.59
10:19 ET20048.48
10:24 ET20048.38
10:26 ET12548.52
10:28 ET39948.34
10:30 ET10048.25
10:32 ET50048.075
10:35 ET20047.59
10:37 ET20047.61
10:39 ET70048.06
10:42 ET10048.18
10:44 ET10048.105
10:46 ET40048.29
10:48 ET10048.36
10:51 ET50048.18
10:53 ET20048.32
10:55 ET62848.545
10:57 ET50048.78
11:00 ET10048.78
11:02 ET20048.81
11:04 ET63248.88
11:08 ET155748.61
11:09 ET10048.71
11:13 ET52748.725
11:15 ET120048.57
11:18 ET140048.77
11:20 ET40048.85
11:22 ET170048.865
11:24 ET20048.82
11:26 ET100048.59
11:27 ET20048.49
11:29 ET29748.66
11:31 ET40048.7
11:33 ET20048.65
11:36 ET60048.52
11:38 ET258648.655
11:40 ET40048.24
11:42 ET40048.51
11:44 ET10048.475
11:45 ET12848.64
11:47 ET96048.505
11:49 ET30048.65
11:51 ET70048.7
11:56 ET110048.58
11:58 ET10048.45
12:00 ET10048.45
12:02 ET58848.3
12:03 ET12848.25
12:12 ET12848.32
12:14 ET10048.05
12:18 ET20048.06
12:21 ET10048.02
12:25 ET10047.99
12:36 ET10047.93
12:39 ET10047.705
12:41 ET10047.72
12:43 ET10047.63
12:48 ET10047.72
12:50 ET10047.58
12:52 ET10047.79
12:59 ET211048.01
01:03 ET10047.965
01:08 ET20048.13
01:12 ET10047.88
01:14 ET10048.09
01:17 ET20047.86
01:19 ET20047.92
01:24 ET10047.89
01:26 ET20047.92
01:30 ET50048.11
01:32 ET10048.11
01:35 ET175447.63
01:42 ET10047.59
01:48 ET123047.75
01:51 ET20047.9
01:55 ET20047.9
02:00 ET10047.915
02:02 ET153048.08
02:04 ET110048.22
02:08 ET10048.3
02:09 ET200048.16
02:15 ET10048.11
02:18 ET1530048.59
02:20 ET28248.07
02:22 ET20048.07
02:26 ET10047.97
02:27 ET20047.91
02:29 ET52847.96
02:31 ET30047.94
02:33 ET10047.91
02:36 ET90048.31
02:40 ET392848.4
02:42 ET100048.27
02:44 ET10048.19
02:51 ET30048.285
02:56 ET10048.18
02:58 ET70048.41
03:02 ET192448.02
03:07 ET30048.115
03:09 ET70048.2
03:12 ET10048.14
03:14 ET20048.06
03:16 ET60048.2
03:20 ET10048.19
03:21 ET160048.07
03:23 ET10048.17
03:25 ET10048.1
03:27 ET70048.32
03:30 ET10048.3
03:32 ET80048.24
03:34 ET20048.26
03:36 ET20048.24
03:38 ET40048.325
03:39 ET40048.335
03:41 ET20048.3
03:43 ET57648.28
03:48 ET20048.26
03:50 ET40048.25
03:52 ET68148.46
03:54 ET171648.34
03:56 ET170048.33
03:57 ET154048.39
03:59 ET3823748.48
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSLNO
Soleno Therapeutics Inc
1.6B
-18.1x
---
United StatesKURA
Kura Oncology Inc
1.6B
-9.7x
---
United StatesSYRE
Spyre Therapeutics Inc
1.5B
-0.4x
---
United StatesEWTX
Edgewise Therapeutics Inc
1.7B
-12.4x
---
United StatesNAMS
NewAmsterdam Pharma Company NV
1.7B
-7.0x
---
United StatesBLTE
Belite Bio Inc
1.5B
-41.8x
---
As of 2024-07-26

Company Information

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.

Contact Information

Headquarters
203 Redwood Shores Parkway, Suite 500REDWOOD CITY, CA, United States 94065
Phone
650-213-8444
Fax
302-655-5049

Executives

Independent Chairman of the Board
Ernest Mario
President, Chief Executive Officer, Chief Operating Officer, Director
Anish Bhatnagar
Chief Financial Officer
James Mackaness
Senior Vice President - Clinical Development
Michael Huang
Senior Vice President - Clinical Operations
Kristen Yen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.6B
Revenue (TTM)
$0.00
Shares Outstanding
34.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-1.39
EPS
$-2.68
Book Value
$4.97
P/E Ratio
-18.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.